CR20230007A - Compuesto de ftalazinona, y método de preparación y uso médico de este. - Google Patents

Compuesto de ftalazinona, y método de preparación y uso médico de este.

Info

Publication number
CR20230007A
CR20230007A CR20230007A CR20230007A CR20230007A CR 20230007 A CR20230007 A CR 20230007A CR 20230007 A CR20230007 A CR 20230007A CR 20230007 A CR20230007 A CR 20230007A CR 20230007 A CR20230007 A CR 20230007A
Authority
CR
Costa Rica
Prior art keywords
preparation
method therefor
medical use
compound
phthalazinone
Prior art date
Application number
CR20230007A
Other languages
English (en)
Inventor
Hongfu Lu
Haibing Guo
Jianbiao Peng
Yongcong Lv
Weiqiang Xing
Baojian Qi
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of CR20230007A publication Critical patent/CR20230007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Se divulgan un compuesto de ftalazinona y un método de preparación para este y el uso médico de este. En particular, se divulgan un compuesto como se representa mediante la fórmula (I), y una sal farmacodinámicamente aceptable, y el uso del compuesto como un receptor de andrógeno (AR) para degradación.
CR20230007A 2020-06-12 2021-06-11 Compuesto de ftalazinona, y método de preparación y uso médico de este. CR20230007A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202010536221 2020-06-12
CN202011147078 2020-10-23
CN202011261665 2020-11-12
CN202110485680 2021-04-30
CN202110614030 2021-06-02
PCT/CN2021/099654 WO2021249534A1 (zh) 2020-06-12 2021-06-11 酞嗪酮类化合物及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
CR20230007A true CR20230007A (es) 2023-06-01

Family

ID=78846889

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230007A CR20230007A (es) 2020-06-12 2021-06-11 Compuesto de ftalazinona, y método de preparación y uso médico de este.

Country Status (16)

Country Link
US (2) US20230131252A1 (es)
EP (1) EP4166550A1 (es)
JP (1) JP2023531390A (es)
KR (1) KR20230024328A (es)
CN (2) CN113801098B (es)
AU (1) AU2021286738A1 (es)
BR (1) BR112022025057A2 (es)
CA (1) CA3186981A1 (es)
CL (1) CL2022003472A1 (es)
CO (1) CO2022017802A2 (es)
CR (1) CR20230007A (es)
IL (1) IL298962A (es)
MX (1) MX2022015562A (es)
PE (1) PE20230610A1 (es)
TW (1) TWI781651B (es)
WO (1) WO2021249534A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220119094A (ko) 2019-12-19 2022-08-26 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
WO2021249534A1 (zh) * 2020-06-12 2021-12-16 上海济煜医药科技有限公司 酞嗪酮类化合物及其制备方法和医药用途
KR102474999B1 (ko) * 2021-05-26 2022-12-07 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
WO2022250224A1 (ko) * 2021-05-26 2022-12-01 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
TW202321219A (zh) 2021-08-11 2023-06-01 大陸商四川海思科製藥有限公司 雜環衍生物及其組合物和藥學上的應用
WO2024054952A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024054953A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230119040A (ko) 2015-01-20 2023-08-14 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법
JP7009466B2 (ja) 2016-10-11 2022-02-10 アルビナス・オペレーションズ・インコーポレイテッド アンドロゲン受容体の標的分解のための化合物および方法
EP3544975B1 (en) 2016-11-22 2022-01-05 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and use
EP3544957A4 (en) 2016-11-22 2020-09-02 Dana-Farber Cancer Institute, Inc. KINASE PROTEIN DEGRADATION BY CONJUGATION OF KINASE PROTEIN INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
CA3050309A1 (en) 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN110194762B (zh) * 2018-02-27 2021-09-10 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途
CN112390852B (zh) 2019-08-14 2022-10-18 上海济煜医药科技有限公司 作为蛋白降解剂的化合物及其制备方法和应用
CN112457367B (zh) 2019-09-06 2022-08-23 上海济煜医药科技有限公司 作为蛋白降解剂的连环类化合物及其制备方法和应用
CN112457366B (zh) 2019-09-06 2024-03-19 江西济民可信集团有限公司 作为蛋白降解剂的并环类化合物及其制备方法和应用
CN112574278A (zh) 2019-09-29 2021-03-30 江西济民可信集团有限公司 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
CA3162523A1 (en) 2019-12-23 2021-07-01 Hongfu LU Protein degradation agent compound preparation method and application
CN113582974B (zh) 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
WO2021249534A1 (zh) * 2020-06-12 2021-12-16 上海济煜医药科技有限公司 酞嗪酮类化合物及其制备方法和医药用途

Also Published As

Publication number Publication date
CL2022003472A1 (es) 2023-06-02
PE20230610A1 (es) 2023-04-13
CN113801098A (zh) 2021-12-17
KR20230024328A (ko) 2023-02-20
US11767312B2 (en) 2023-09-26
WO2021249534A1 (zh) 2021-12-16
TW202146400A (zh) 2021-12-16
IL298962A (en) 2023-02-01
JP2023531390A (ja) 2023-07-24
US20230242510A1 (en) 2023-08-03
CA3186981A1 (en) 2021-12-16
MX2022015562A (es) 2023-01-30
AU2021286738A1 (en) 2023-01-19
CO2022017802A2 (es) 2023-03-17
CN113801098B (zh) 2023-05-30
TWI781651B (zh) 2022-10-21
EP4166550A1 (en) 2023-04-19
CN116082311A (zh) 2023-05-09
US20230131252A1 (en) 2023-04-27
BR112022025057A2 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
MX2022015562A (es) Compuesto de ftalazinona, y metodo de preparacion y uso medico de este.
JOP20220155A1 (ar) مشتقات البيرازول مفيدة كعوامل مضادة للسرطان
CR20220258A (es) Inhibidores de kras g12c
ZA202208051B (en) Protein degradation agent compound preparation method and application
TN2018000319A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
PH12019550154A1 (en) Azetidine derivative
MX2021013531A (es) Inhibidores de cdk.
ZA202307945B (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
MX2021012105A (es) Compuestos de pirrol.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2019013816A (es) Compuesto usado como regulador de la autofagia, metodo de preparacion y sus usos.
MX2023001071A (es) Tratamiento de la migraña.
MX2023009037A (es) Compuesto de pirimidopirano.
MX2022006653A (es) Compuestos para modular la actividad de fxr y usos de los mismos.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
CR20210495A (es) Compuestos macrocíclicos como agonistas de sting
MX2021007247A (es) Derivados de rapamicina.
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
MX2021011007A (es) Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.
MX2021009045A (es) Moduladores de transporte nuclear que contienen acrilo y uso de los mismos.
MX2021009717A (es) Sulfonamidas biciclicas.